Generic Name: – Flavoxate Hydrochloride
Therapeutic Class: – Urinary Spasmolytic
Dosage Form: – Tablets
Each Film Coated U-RELIEF Contains 200 mg – Flavoxate Hydrochloride.
- U-RELIEF (Flavoxate) inhibits the enzyme Phosphodiesterase (PDE). This Causes an increase in cyclic adenosine monophosphate level (cAMP), Which results in decrease in concentration of free calcium ion ( Ca+2).
- U-RELIEF (Flavoxate) also possesses the property of blocking the action of slow calcium ion channels. This action is fairly selective to urinary smooth muscles, and effects on blood vessels are negligible.
- U-RELIEF (Flavoxate) is reported to have a local anesthetic and analgesics action.
- Absorption : U-RELIEF (Flavoxate) is completely absorbed from the gastrointestinal tract.
- Distribution : U-RELIEF (Flavoxate) is distributed through the various body tissues, the highest concentration of which is found in the liver, kidney and urinary bladder.
- Metabolism : U-RELIEF (Flavoxate) undergoes first metabolism. It is metabolized to MFCA (Methyl Flavone carboxylic acid), an active metabolite.
- Excretion : U-RELIEF (Flavoxate) is excreted mainly in the urine as MFCA.
- Urinary Tract Infection
- Irritative urinary symptoms following TURP / Prostatectomy / Cystoscopy.
- Urinary urge incontinence due to detrusor Instability.
- OAB (Over Active Bladder)
U-Relief is indicated in urinary tract infections for providing symptomatic relief of Dysuria (Painful micturition), urgency, Nocturia (Need to urinate during night), Suprapubic pain, Frequency and incontinence.
Though antibiotics take five to seven days to eradicate the infections, U-RELIEF (Flavoxate) when co-prescribed is envisaged to promptly relieve the associated symptoms with the intiation of therapy. In non-infectious cases of bladder inflammation U-RELIEF (Flavoxate) alone can provide prompt symptomatic relief.
IN CATHETERISATION U-RELIEF (Flavoxate) improves the drainage capacity of catheter and decreases the chances of catheter induced infection.
Usual recommended dose of U-RELIEF (Flavoxate) is one tablet three or four times a day.
For urinary incontinence due to detrusor instability is one to two tablets three times a day for a minimum of three months.
Drug Interactions : – Flavoxate has no known drug interaction.
Precautions : – Flavoxate should be given cautiously in patients with suspected glaucoma. Flavoxate can be given to children above 12 years of age. Although there is no known teratogenic or embryo genic effect, it is not advisable to give Flavoxate during the first three months of pregnancy.
Adverse effects : – Nausea, vomiting, dry mouth (low incidences) headache (low incidences), blurred vision (low incidences).
CONTRAINDICATIONS: – Gastrointestinal obstruction or hemorrhage, ileus, achalasia, obstructive uropathies of the lower urinary tract, hypersensitivity.